Comparative safety of thrombolytic agents

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Thrombolytic therapy is crucial for acute myocardial infarction (AMI).
• Available agents include streptokinase, alteplase (tissue plasminogen activator), and anistreplase.
• These agents demonstrate comparable efficacy in preserving left ventricular function and reducing mortality post-AMI.

Purpose of the Study:

• To compare the safety profiles of available thrombolytic agents for acute myocardial infarction.
• To evaluate the incidence of adverse events associated with streptokinase, alteplase, and anistreplase.
• To inform clinical decision-making regarding thrombolytic agent selection based on risk-benefit assessment.

Main Methods:

• Review of clinical trial data comparing thrombolytic agents.
• Analysis of safety profiles, including cerebral hemorrhage, allergic reactions, and hypotension.
• Consideration of reinfarction rates associated with different agents.
• Reference to findings from the Third International Study of Infarct Survival (ISIS-3).

Main Results:

• Alteplase and anistreplase are associated with a high incidence of cerebral hemorrhage.
• Streptokinase has a low rate of cerebral hemorrhage but a higher risk of allergic reactions and hypotension.
• Alteplase shows a lower reinfarction rate compared to streptokinase and anistreplase.
• Hypotension is a risk with all agents, but more common with streptokinase and anistreplase.

Conclusions:

• Thrombolytic agents for AMI are equally effective, necessitating selection based on safety profiles.
• Patient-specific risk assessment for adverse events (e.g., hemorrhage, allergy) is paramount.
• Factors like cost and administration convenience may influence agent choice alongside safety.